Cargando…

The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing

INTRODUCTION: Neurofibromatosis type 1 (NF1) is a common Mendelian multi-system disorder that is characterized by café-au-lait spots (CLS), axillary freckling, optic glioma and plexiform neurofibroma. Various mutations of the NF1 gene are widely accepted to be the main cause of this disease, while w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Xu, Song, Liu, Renwang, Shi, Tao, Li, Xiongfei, Li, Xuebing, Chen, Gang, Liu, Hongyu, Zhou, Qinghua, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826295/
https://www.ncbi.nlm.nih.gov/pubmed/29503567
http://dx.doi.org/10.2147/OTT.S156998
_version_ 1783302322029330432
author Yang, Fan
Xu, Song
Liu, Renwang
Shi, Tao
Li, Xiongfei
Li, Xuebing
Chen, Gang
Liu, Hongyu
Zhou, Qinghua
Chen, Jun
author_facet Yang, Fan
Xu, Song
Liu, Renwang
Shi, Tao
Li, Xiongfei
Li, Xuebing
Chen, Gang
Liu, Hongyu
Zhou, Qinghua
Chen, Jun
author_sort Yang, Fan
collection PubMed
description INTRODUCTION: Neurofibromatosis type 1 (NF1) is a common Mendelian multi-system disorder that is characterized by café-au-lait spots (CLS), axillary freckling, optic glioma and plexiform neurofibroma. Various mutations of the NF1 gene are widely accepted to be the main cause of this disease, while whether there are still certain other modifier genes that could influence the phenotypes of NF1 is our concern. PATIENTS AND METHODS: One proband and his father are involved, who are characterized by plexiform neurofibroma and cutaneous neurofibroma, respectively. Enhanced Computed tomography (CT) and Positron emission tomography-CT (PET-CT) were taken to collect the radiographic data, and the specimens of this neurofibroma as well as the blood samples from the father and son were sent for panel mutation screening of 295 tumor-related genes based on next-generation screening. Furthermore, the NF1 gene mutations were referred with Canis lupus familiaris, Rattus norvegicus, Gallus gallus, Danio rerio, and Drosophila melanogaster NF1 sequencing for evolutionary conservativeness and then analyzed in Condel databases for pathogenicity prediction. RESULTS: The radiography indicated that the benign plexiform neurofibroma only occurred in the son. Also, TP53, FANCA, BCL6, PIK3C2G, RNF43, FGFR4, FLT3, ERBB2, PAK7, NSD1, MEN1 and TSC1 were uniquely found mutated in the son, which could be candidates as new modifier genes; besides, RNF43 was also mutated in public neurofibroma seuquencing data. By KEGG pathway annotation, phosphoinositide-3-kinase-Akt pathway was altered in both the public plexiform neurofibroma sample and in our proband patient. CONCLUSION: This study reexamined the background germline mutations and suggested their potential value as modifier genes that may influence the phenotype heterogenity.
format Online
Article
Text
id pubmed-5826295
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58262952018-03-02 The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing Yang, Fan Xu, Song Liu, Renwang Shi, Tao Li, Xiongfei Li, Xuebing Chen, Gang Liu, Hongyu Zhou, Qinghua Chen, Jun Onco Targets Ther Original Research INTRODUCTION: Neurofibromatosis type 1 (NF1) is a common Mendelian multi-system disorder that is characterized by café-au-lait spots (CLS), axillary freckling, optic glioma and plexiform neurofibroma. Various mutations of the NF1 gene are widely accepted to be the main cause of this disease, while whether there are still certain other modifier genes that could influence the phenotypes of NF1 is our concern. PATIENTS AND METHODS: One proband and his father are involved, who are characterized by plexiform neurofibroma and cutaneous neurofibroma, respectively. Enhanced Computed tomography (CT) and Positron emission tomography-CT (PET-CT) were taken to collect the radiographic data, and the specimens of this neurofibroma as well as the blood samples from the father and son were sent for panel mutation screening of 295 tumor-related genes based on next-generation screening. Furthermore, the NF1 gene mutations were referred with Canis lupus familiaris, Rattus norvegicus, Gallus gallus, Danio rerio, and Drosophila melanogaster NF1 sequencing for evolutionary conservativeness and then analyzed in Condel databases for pathogenicity prediction. RESULTS: The radiography indicated that the benign plexiform neurofibroma only occurred in the son. Also, TP53, FANCA, BCL6, PIK3C2G, RNF43, FGFR4, FLT3, ERBB2, PAK7, NSD1, MEN1 and TSC1 were uniquely found mutated in the son, which could be candidates as new modifier genes; besides, RNF43 was also mutated in public neurofibroma seuquencing data. By KEGG pathway annotation, phosphoinositide-3-kinase-Akt pathway was altered in both the public plexiform neurofibroma sample and in our proband patient. CONCLUSION: This study reexamined the background germline mutations and suggested their potential value as modifier genes that may influence the phenotype heterogenity. Dove Medical Press 2018-02-21 /pmc/articles/PMC5826295/ /pubmed/29503567 http://dx.doi.org/10.2147/OTT.S156998 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yang, Fan
Xu, Song
Liu, Renwang
Shi, Tao
Li, Xiongfei
Li, Xuebing
Chen, Gang
Liu, Hongyu
Zhou, Qinghua
Chen, Jun
The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
title The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
title_full The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
title_fullStr The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
title_full_unstemmed The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
title_short The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
title_sort investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826295/
https://www.ncbi.nlm.nih.gov/pubmed/29503567
http://dx.doi.org/10.2147/OTT.S156998
work_keys_str_mv AT yangfan theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT xusong theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT liurenwang theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT shitao theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT lixiongfei theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT lixuebing theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT chengang theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT liuhongyu theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT zhouqinghua theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT chenjun theinvestigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT yangfan investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT xusong investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT liurenwang investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT shitao investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT lixiongfei investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT lixuebing investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT chengang investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT liuhongyu investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT zhouqinghua investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing
AT chenjun investigationforpotentialmodifiergenesinpatientswithneurofibromatosistype1basedonnextgenerationsequencing